Xeris Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $92,100 | $83,127 | $85,807 | $74,380 |
Gross Profit | 79,588 | 69,843 | 66,728 | 63,384 |
EBITDA | -21,120 | 12,328 | 14,127 | 11,078 |
EBIT | -24,154 | 9,118 | 11,081 | 7,889 |
Net Income | -31,101 | 2,234 | 11,081 | 621 |
Net Change In Cash | 92,100 | 83,127 | 85,807 | 74,380 |
Free Cash Flow | 8,054 | 9,545 | 19,710 | 18,069 |
Cash | 121,747 | 111,750 | 111,042 | 91,598 |
Basic Shares | 172,823 | 177,631 | 180,071 | 177,617 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $291,845 | $203,070 | $163,914 | $110,248 |
Gross Profit | 238,433 | 166,238 | 135,269 | 87,614 |
EBITDA | 12,710 | -13,994 | -23,735 | -69,314 |
EBIT | 554 | -26,619 | -36,895 | -81,982 |
Net Income | 554 | -54,836 | -62,255 | -94,660 |
Net Change In Cash | 291,845 | 203,070 | 163,914 | 110,248 |
Free Cash Flow | 27,930 | -37,849 | -49,286 | -103,415 |
Cash | 111,042 | 71,621 | 67,449 | 121,966 |
Basic Shares | 172,742 | 146,773 | 137,674 | 135,628 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.01 |
2026-03-31 | $0.01 |
2025-12-31 | $0.06 |
2025-09-30 | $0.003 |